Processa Pharmaceuticals, Inc. - Common Stock (PCSA)
0.2940
-0.0460 (-13.53%)
NASDAQ · Last Trade: Apr 7th, 9:19 PM EDT
Detailed Quote
Previous Close
0.3400
Open
0.3400
Bid
0.2800
Ask
0.2840
Day's Range
0.2687 - 0.3400
52 Week Range
0.2400 - 3.305
Volume
1,319,565
Market Cap
1.55M
PE Ratio (TTM)
-0.0756
EPS (TTM)
-3.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,801,894
Chart
About Processa Pharmaceuticals, Inc. - Common Stock (PCSA)
Processa Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of innovative therapeutic solutions for patients with unmet medical needs. The company primarily concentrates on advancing treatments for various cancer types and gastrointestinal disorders by utilizing its proprietary drug candidates. Through rigorous research and clinical trials, Processa aims to improve patient outcomes and enhance the quality of life for those affected by serious health conditions. Its strategic approach includes leveraging repurposed existing therapies as well as developing novel compounds, highlighting its commitment to addressing significant healthcare challenges. Read More
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, reported that dosing of the first patient in its phase 2 clinical trial evaluating NGC-Cap has begun. The clinical trial is evaluating NGC-Cap for the treatment of advanced or metastatic breast cancer. NGC-Cap combines the administration of PCS6422, PCSA’s irreversible dihydropyrimidine dehydrogenase (“DPD”) enzyme inhibitor, with low doses of capecitabine.
Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety. The company today announced that management will hold one-on-one meetings with investors and deliver a company presentation at the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel. The recorded presentation will be available on demand beginning Monday, September 9, 2024, at 7 a.m. ET. In addition, Processa’s management will hold meetings with clinicians, researchers, industry key opinion leaders and potential partners at the European Society for Medical Oncology (“ESMO”) Congress 2024. ESMO Congress 2024 will be held September 13-17, 2024, in Barcelona.
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today provided updates on its product pipeline, upcoming milestones and business activities. According to the updates, a Phase 2 trial with NGC-Cap is underway in patients with breast cancer. In addition, preclinical studies showed that NGC-Iri delivers more cancer-killing SN-38 molecules to the tumor than Onivyde(R) or irinotecan.
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive data from two preclinical studies. The data support the potential for the Next Generation irinotecan (“NGC-Iri”), the prodrug of SN-38, which is the active anticancer metabolite of irinotecan, to have improved efficacy and a better side effect profile compared with the commonly used FDA-approved cancer treatments irinotecan and Onivyde(R) (the liposomal formation of irinotecan). The two studies demonstrated that NCG-Iri delivered more cancer-killing SN-38 molecules to the tumor than irinotecan and Onivyde(R). In addition, less SN-38 accumulated in non-cancer tissues, such as muscle, after NGC-Iri administration than after irinotecan or Onivyde(R) administration.
